Tigecycline as a second-line agent for legionnaires' disease in severely ill patients

Deepika Slawek, Diana Altshuler, Yanina Dubrovskaya, Eddie Louie

Research output: Contribution to journalArticle

Abstract

Treatment of Legionnaires' disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

Original languageEnglish (US)
Article numberofx184
JournalOpen Forum Infectious Diseases
Volume4
Issue number4
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

    Fingerprint

Keywords

  • Legionnaires' disease
  • Tigecycline

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this